Drug Trial Radar · NCT07619157
A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 2, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus
Conditions
- Type2 Diabetes Mellitus
- Chronic Kidney Disease
Interventions
ONO-3310Drug
Single oral dose of ONO-3310 to HV
PlaceboDrug
Single oral dose of Placebo to HV
ONO-3310Drug
Multiple oral dose of ONO-3310 to HV
PlaceboDrug
Multiple oral dose of Placebo to HV
ONO-3310Drug
Single or multiple oral dose of ONO-3310 to CKD patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: Through study completion, typically 10days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Maximum plasma observed concentration (Cmax)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Time to reach maximum observed concentration (Tmax)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24h)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Area under the plasma concentration versus time curve from time zero to infinity (AUCinf)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Area under the plasma concentration versus time curve from time zero to time of last measurable concentration (AUClast)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Elimination half-life (T1/2)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Apparent total clearance (CL/F)Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)
- Urinary excretion rate of unchanged drugTime frame: Up to 6 days (HV single)
- Pharmacodynamics (evaluation of Urinary albumin-to-creatinine ratio)Time frame: Up to 74 days (CKD)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Souseikai Hakata Clinic
Fukuoka, Fukuoka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.